Lv4
422 积分 2022-09-19 加入
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
5小时前
已完结
safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line
5小时前
已完结
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
29天前
已完结
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
30天前
已完结
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial
1个月前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
1个月前
已完结
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
1个月前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Radiation Pneumonitis
1个月前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
